atrasentan has been researched along with Ventricular Dysfunction, Left in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayajiki, K; Fukumoto, T; Geddawy, A; Imamura, T; Matsumura, Y; Ohkita, M; Okamura, T; Tawa, M; Yamashita, N | 1 |
| Chen, CC; Hsu, YJ; Lee, TM | 1 |
| Fujita, M; Kanazawa, M; Matsumoto, N; Matsumura, Y; Takaoka, M; Yamamoto, S | 1 |
3 other study(ies) available for atrasentan and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Effects of exogenous big endothelin-1 on postischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
Topics: Animals; Aspartic Acid Endopeptidases; Atrasentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Male; Metalloendopeptidases; Myocardial Reperfusion Injury; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfonylurea Compounds; Ventricular Dysfunction, Left | 2011 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; Dinoprost; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gout Suppressants; Hypertrophy, Left Ventricular; Hyperuricemia; Isoprostanes; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; RNA, Messenger; Spin Labels; Superoxides; Time Factors; Up-Regulation; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2011 |
Effects of ET(A) and ET(B) receptor blockade on post-ischemic cardiac dysfunction and norepinephrine overflow in isolated rat hearts.
Topics: Animals; Atrasentan; Cardiovascular Agents; Coronary Circulation; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Myocardium; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sympathetic Nervous System; Time Factors; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Pressure | 2004 |